Managing Chronic Asthma in Adults

When managing chronic asthma in adults, it is important to consider the patient’s current treatment plan and symptoms. In this scenario, the patient is already taking a combination inhaler and is experiencing suboptimal control of her asthma. It is important to note that this is not an acute attack and the children’s guidelines do not apply. Antibiotics are not recommended as the symptoms are not consistent with an infective exacerbation. Increasing the usage of salbutamol is also not recommended as the patient needs better overall control of her symptoms. Instead, the dose of the inhaled corticosteroid should be increased, which is in line with the next step in the treatment of asthma in adults according to the British Thoracic Society guidelines. It is important for healthcare professionals to be familiar with both SIGN and NICE guidance and be able to compare and contrast their advice.

The patient has good inhaler technique but needs to wait approximately 30 seconds before repeating the dose. Holding the breath for at least 10 seconds after administering the medication is recommended, but holding it for longer is not necessary. Advising the patient to hold their breath for at least 30 seconds after administering the dose is incorrect.

Proper Inhaler Technique for Metered-Dose Inhalers

Metered-dose inhalers are commonly used to treat respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). However, it is important to use them correctly to ensure that the medication is delivered effectively to the lungs. Here is a step-by-step guide to proper inhaler technique:

1. Remove the cap and shake the inhaler.

2. Breathe out gently.

3. Place the mouthpiece in your mouth and begin to breathe in slowly and deeply.

4. As you start to inhale, press down on the canister to release the medication. Continue to inhale steadily and deeply.

5. Hold your breath for 10 seconds, or as long as is comfortable.

6. If a second dose is needed, wait approximately 30 seconds before repeating steps 1-5.

It is important to note that inhalers should only be used for the number of doses specified on the label. Once the inhaler is empty, a new one should be started. By following these steps, patients can ensure that they are using their inhaler correctly and receiving the full benefits of their medication.

A provoked pulmonary embolism, which occurred after surgery and immobilisation in a middle-aged man, typically requires treatment for at least 3 months. However, the duration of treatment may need to be extended or specialist referral may be necessary depending on the patient’s leg and respiratory symptoms. Indefinite anticoagulation is not recommended unless the problem is recurrent or the patient has thrombophilia. Referral to a haematologist is also not necessary unless the treatment is unsuccessful or the patient experiences further thrombosis issues. Anticoagulation for 6 months may be considered for unprovoked pulmonary embolism, but in this case, the patient’s condition was provoked by surgery and immobilisation.

Management of Pulmonary Embolism

Pulmonary embolism (PE) is a serious condition that requires prompt management. The National Institute for Health and Care Excellence (NICE) updated their guidelines on the management of venous thromboembolism (VTE) in 2020, with some key changes. One of the significant changes is the recommendation to use direct oral anticoagulants (DOACs) as the first-line treatment for most people with VTE, including those with active cancer. Another change is the increasing use of outpatient treatment for low-risk PE patients, determined by a validated risk stratification tool.

Anticoagulant therapy is the cornerstone of VTE management. The guidelines recommend using apixaban or rivaroxaban as the first-line treatment for PE, followed by LMWH, dabigatran, edoxaban, or a vitamin K antagonist (VKA) if necessary. For patients with active cancer, DOACs are now recommended instead of LMWH. The length of anticoagulation depends on whether the VTE was provoked or unprovoked, with treatment typically lasting for at least three months. Patients with unprovoked VTE may continue treatment for up to six months, depending on their risk of recurrence and bleeding.

In cases of haemodynamic instability, thrombolysis is recommended as the first-line treatment for massive PE with circulatory failure. Other invasive approaches may also be considered where appropriate facilities exist. Patients who have repeat pulmonary embolisms, despite adequate anticoagulation, may be considered for inferior vena cava (IVC) filters. However, the evidence base for IVC filter use is weak, and further studies are needed.

Legionnaires Disease: Causes, Symptoms, and Treatment

Legionnaires disease is a type of pneumonia caused by the Gram-negative bacillus, Legionella pneumophilia. The disease is usually associated with contaminated water cooling systems, air conditioning units, or showers. However, sporadic cases can also occur. People who travel and stay in hotels or resorts with poorly maintained air conditioning or showers are at risk of exposure to the bacteria.

The symptoms of Legionnaires disease can vary and may include gastrointestinal upset, flu-like symptoms, diarrhea, jaundice, headache, and confusion. Patients may also experience a decrease in their white blood cell count, resulting in lymphopenia. Additionally, the disease can cause the syndrome of inappropriate antidiuretic hormone secretion (SIADH), leading to hyponatremia. Abnormal liver and renal biochemistry occur in about half of patients.

Amoxicillin is not an effective treatment for Legionnaires disease. Instead, macrolides such as erythromycin or clarithromycin are typically used. Some doctors prefer to use quinolones as the first choice of treatment.

To ensure adequate drug delivery, it is important to use proper inhaler technique, which includes shaking the inhaler, taking a slow breath in, holding the breath for 10 seconds, and waiting 30 seconds between doses.

Proper Inhaler Technique for Metered-Dose Inhalers

Metered-dose inhalers are commonly used to treat respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). However, it is important to use them correctly to ensure that the medication is delivered effectively to the lungs. Here is a step-by-step guide to proper inhaler technique:

1. Remove the cap and shake the inhaler.

2. Breathe out gently.

3. Place the mouthpiece in your mouth and begin to breathe in slowly and deeply.

4. As you start to inhale, press down on the canister to release the medication. Continue to inhale steadily and deeply.

5. Hold your breath for 10 seconds, or as long as is comfortable.

6. If a second dose is needed, wait approximately 30 seconds before repeating steps 1-5.

It is important to note that inhalers should only be used for the number of doses specified on the label. Once the inhaler is empty, a new one should be started. By following these steps, patients can ensure that they are using their inhaler correctly and receiving the full benefits of their medication.

Bronchiectasis as a Possible Diagnosis for Chronic Non-Productive Cough

Consider bronchiectasis as a possible diagnosis for a patient with a chronic non-productive cough, especially if the patient is a non-smoker. While other diagnoses are also possible, bronchiectasis is more likely if the patient doesn’t exhibit symptoms such as night sweats, weight loss, or the growth of Pseudomonas. It is important to note that a chest X-ray may not always show abnormalities in patients with bronchiectasis, and a CT-scan is often necessary for an accurate diagnosis. Therefore, if a patient presents with a chronic non-productive cough, bronchiectasis should be considered as a possible diagnosis, particularly in non-smokers.

Patients with COPD who experience frequent exacerbations and meet specific criteria are recommended to undergo azithromycin prophylaxis. According to NICE guidelines, this treatment should be considered for non-smokers, patients who have already undergone pulmonary rehabilitation and are on the maximum inhaled therapy, and those who have had more than four exacerbations resulting in hospitalization with sputum production. Before starting the antibiotics, patients should undergo a CT scan to eliminate other lung pathologies.

The National Institute for Health and Care Excellence (NICE) updated its guidelines on the management of chronic obstructive pulmonary disease (COPD) in 2018. The guidelines recommend general management strategies such as smoking cessation advice, annual influenza vaccination, and one-off pneumococcal vaccination. Pulmonary rehabilitation is also recommended for patients who view themselves as functionally disabled by COPD.

Bronchodilator therapy is the first-line treatment for patients who remain breathless or have exacerbations despite using short-acting bronchodilators. The next step is determined by whether the patient has asthmatic features or features suggesting steroid responsiveness. NICE suggests several criteria to determine this, including a previous diagnosis of asthma or atopy, a higher blood eosinophil count, substantial variation in FEV1 over time, and substantial diurnal variation in peak expiratory flow.

If the patient doesn’t have asthmatic features or features suggesting steroid responsiveness, a long-acting beta2-agonist (LABA) and long-acting muscarinic antagonist (LAMA) should be added. If the patient is already taking a short-acting muscarinic antagonist (SAMA), it should be discontinued and switched to a short-acting beta2-agonist (SABA). If the patient has asthmatic features or features suggesting steroid responsiveness, a LABA and inhaled corticosteroid (ICS) should be added. If the patient remains breathless or has exacerbations, triple therapy (LAMA + LABA + ICS) should be offered.

NICE only recommends theophylline after trials of short and long-acting bronchodilators or to people who cannot use inhaled therapy. Azithromycin prophylaxis is recommended in select patients who have optimised standard treatments and continue to have exacerbations. Mucolytics should be considered in patients with a chronic productive cough and continued if symptoms improve.

Cor pulmonale features include peripheral oedema, raised jugular venous pressure, systolic parasternal heave, and loud P2. Loop diuretics should be used for oedema, and long-term oxygen therapy should be considered. Smoking cessation, long-term oxygen therapy in eligible patients, and lung volume reduction surgery in selected patients may improve survival in patients with stable COPD. NICE doesn’t recommend the use of ACE-inhibitors, calcium channel blockers, or alpha blockers

Cognitive Therapy and Breathing Exercises for Hyperventilation Syndrome

Two studies have shown that cognitive therapy and breathing exercises can effectively treat hyperventilation syndrome. This condition often leads to pleuritic chest pain without any apparent cause. During therapy sessions, specific anxiety triggers can be identified and addressed. However, for those with chronic hyperventilation syndrome, cognitive therapy and breathing exercises can provide relief and improve overall quality of life. With these treatments, patients can learn to control their breathing and reduce symptoms of hyperventilation syndrome.

Polycythaemia can be a long-term complication of COPD that may be detected through a full blood count. This condition is caused by chronic hypoxia, which triggers the kidneys to produce more erythropoietin and increase haemoglobin levels. Thrombocytopenia, on the other hand, is a reduction in platelet count that can be caused by various factors such as medication side effects, vitamin deficiencies, or disseminated intravascular coagulation. Conversely, thrombocythemia, or an elevated platelet count, can be caused by inflammation, malignancy, or infection. Leukopenia, or a decrease in white blood cells, can be a result of acute infection or serious conditions like HIV or cancer. Finally, anaemia, or a decrease in haemoglobin concentration, can be caused by deficiencies in iron, vitamin B12, or folic acid.

Understanding COPD: Symptoms and Diagnosis

Chronic obstructive pulmonary disease (COPD) is a common medical condition that includes chronic bronchitis and emphysema. Smoking is the leading cause of COPD, and patients with mild disease may only need occasional use of a bronchodilator, while severe cases may result in frequent hospital admissions due to exacerbations. Symptoms of COPD include a productive cough, dyspnea, wheezing, and in severe cases, right-sided heart failure leading to peripheral edema.

To diagnose COPD, doctors may recommend post-bronchodilator spirometry to demonstrate airflow obstruction, a chest x-ray to check for hyperinflation, bullae, and flat hemidiaphragm, and to exclude lung cancer. A full blood count may also be necessary to exclude secondary polycythemia, and body mass index (BMI) calculation is important. The severity of COPD is categorized using the FEV1, with a ratio of less than 70% indicating airflow obstruction. The grading system has changed following the 2010 NICE guidelines, with Stage 1 – mild now including patients with an FEV1 greater than 80% predicted but with a post-bronchodilator FEV1/FVC ratio of less than 0.7. Measuring peak expiratory flow is of limited value in COPD, as it may underestimate the degree of airflow obstruction.

In summary, COPD is a common condition caused by smoking that can result in a range of symptoms and severity. Diagnosis involves various tests to check for airflow obstruction, exclude lung cancer, and determine the severity of the disease.

Diagnosis and Management of Community-Acquired Pneumonia

When a patient presents with signs and symptoms of a lower respiratory tract infection, it is important to differentiate between non-pneumonic and pneumonic infections. In cases of non-pneumonic infections, antibiotics should not be given unless the patient is showing signs of severity. However, if chest signs are present, a diagnosis of community-acquired pneumonia should be made, and early administration of antibiotics is crucial to prevent the development of severe illness.

While chest radiography and CRP levels are not useful in the acute setting of pneumonia, they may be indicated in certain cases. A chest x-ray may be necessary if treatment response is unsatisfactory or in smokers during the convalescent period. CRP levels can be helpful in making a decision about antibiotic treatment for individuals with symptoms of LRTI but no signs.

According to NICE guidelines, antibiotic therapy should not be routinely offered if the CRP concentration is less than 20 mg/litre. A delayed antibiotic prescription should be considered if the CRP concentration is between 20 mg/litre and 100 mg/litre, and antibiotic therapy should be offered if the CRP concentration is greater than 100 mg/litre. By following these guidelines, healthcare providers can effectively diagnose and manage community-acquired pneumonia.

To ensure effective use of an inhaler, it is important to follow proper technique. Asthma UK provides helpful guidance on inhaler usage for different types of inhalers.

For a pressurised metered dose inhaler, it is advised to hold your breath for 10 seconds after inhaling the medication. This allows sufficient time for the medication to reach the airways, rather than being exhaled prematurely.

To use the inhaler, breathe in slowly and steadily while pressing down on the canister in one smooth motion. If a second dose is needed, wait for about 30 seconds before repeating to avoid any interference with the delivery of the medication.

Proper Inhaler Technique for Metered-Dose Inhalers

Metered-dose inhalers are commonly used to treat respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). However, it is important to use them correctly to ensure that the medication is delivered effectively to the lungs. Here is a step-by-step guide to proper inhaler technique:

1. Remove the cap and shake the inhaler.

2. Breathe out gently.

3. Place the mouthpiece in your mouth and begin to breathe in slowly and deeply.

4. As you start to inhale, press down on the canister to release the medication. Continue to inhale steadily and deeply.

5. Hold your breath for 10 seconds, or as long as is comfortable.

6. If a second dose is needed, wait approximately 30 seconds before repeating steps 1-5.

It is important to note that inhalers should only be used for the number of doses specified on the label. Once the inhaler is empty, a new one should be started. By following these steps, patients can ensure that they are using their inhaler correctly and receiving the full benefits of their medication.

Identifying the Correct Diagnosis for Breathlessness

A variety of conditions can cause breathlessness, making it difficult to arrive at a correct diagnosis. For instance, someone with shortness of breath and bibasal crepitations may be misdiagnosed with heart failure. However, a normal ECG and BNP can rule out cardiac failure.

To identify the correct diagnosis, a thorough clinical examination is necessary. In this case, the presence of finger clubbing narrows the options down to bronchiectasis, carcinoma, and pulmonary fibrosis. The additional features of cyanosis and bibasal fine crepitations strongly suggest that pulmonary fibrosis is the underlying diagnosis.

By carefully considering all the symptoms and conducting a comprehensive examination, healthcare professionals can accurately diagnose and treat patients with breathlessness.

Investigating and Diagnosing COPD

To diagnose COPD, NICE recommends considering patients over 35 years of age who are smokers or ex-smokers and have symptoms such as chronic cough, exertional breathlessness, or regular sputum production. The following investigations are recommended: post-bronchodilator spirometry to demonstrate airflow obstruction, chest x-ray to exclude lung cancer and identify hyperinflation, bullae, or flat hemidiaphragm, full blood count to exclude secondary polycythaemia, and BMI calculation. The severity of COPD is categorized using the FEV1, with Stage 1 being mild and Stage 4 being very severe. Measuring peak expiratory flow is of limited value in COPD as it may underestimate the degree of airflow obstruction. It is important to note that the grading system has changed following the 2010 NICE guidelines, with Stage 1 now including patients with an FEV1 greater than 80% predicted but a post-bronchodilator FEV1/FVC ratio less than 70%.

Understanding Acute Asthma: Symptoms and Severity

Acute asthma is a condition that is typically observed in individuals who have a history of asthma. It is characterized by worsening dyspnea, wheezing, and coughing that doesn’t respond to salbutamol. Acute asthma attacks may be triggered by respiratory tract infections. Patients with acute severe asthma are classified into three categories: moderate, severe, or life-threatening.

Moderate acute asthma is characterized by a peak expiratory flow rate (PEFR) of 50-75% of the best or predicted value, normal speech, a respiratory rate (RR) of less than 25 breaths per minute, and a pulse rate of less than 110 beats per minute. Severe acute asthma is characterized by a PEFR of 33-50% of the best or predicted value, inability to complete sentences, an RR of more than 25 breaths per minute, and a pulse rate of more than 110 beats per minute. Life-threatening acute asthma is characterized by a PEFR of less than 33% of the best or predicted value, oxygen saturation levels of less than 92%, a silent chest, cyanosis or feeble respiratory effort, bradycardia, dysrhythmia or hypotension, and exhaustion, confusion, or coma.

It is important to note that a normal pCO2 in an acute asthma attack indicates exhaustion and should be classified as life-threatening. Understanding the symptoms and severity of acute asthma can help healthcare professionals provide appropriate treatment and management for patients experiencing an acute asthma attack.

Overlapping Symptoms of COPD and Other Respiratory Diagnoses

There are several respiratory diagnoses that can present with similar symptoms to COPD, including asthma, bronchiectasis, congestive cardiac failure, and bronchial carcinoma. It is important for healthcare professionals to consider these alternative diagnoses when assessing patients with COPD symptoms.

The basics of history and examination are crucial in forming a list of possibilities and guiding any investigation. In some cases, patients may have a rarer condition such as bronchopulmonary dysplasia or obliterative bronchiolitis.

In the case of this patient, the underlying diagnosis is bronchiectasis caused by childhood pneumonia. This has resulted in chronic sputum production and the presence of clubbing, ruling out asthma, COPD, and congestive cardiac failure. While bronchial carcinoma can also cause finger clubbing and focal chest signs, it is less likely in this case due to the patient’s history and other clinical features. Overall, healthcare professionals should always keep in mind the possibility of an alternative diagnosis when assessing patients with COPD symptoms.

Allergic Reactions and MSG Syndrome in Chinese Cuisine

Chinese cuisine is known for its use of cashew nuts and peanut oil in many dishes, which can pose a risk for patients with peanut allergies. Anaphylactic reactions may occur with cashew nuts, while peanut oil can also trigger allergic reactions. Additionally, monosodium glutamate (MSG), a common flavor enhancer in Chinese food, can cause the MSG syndrome. Symptoms of this syndrome include sudden onset headache, heartburn, palpitations, sweating, swelling, and flushing of the face. Tingling or increased facial pressure may also be reported. While the condition is generally self-limited and resolves on its own, antihistamines may be helpful in some cases. It is important to note that the MSG syndrome is unlikely to cause shock, which is not consistent with the patient’s presentation of hypotension.

The diagnosis of COPD cannot be determined through peak expiratory flow.

Investigating and Diagnosing COPD

To diagnose COPD, NICE recommends considering patients over 35 years of age who are smokers or ex-smokers and have symptoms such as chronic cough, exertional breathlessness, or regular sputum production. The following investigations are recommended: post-bronchodilator spirometry to demonstrate airflow obstruction, chest x-ray to exclude lung cancer and identify hyperinflation, bullae, or flat hemidiaphragm, full blood count to exclude secondary polycythaemia, and BMI calculation. The severity of COPD is categorized using the FEV1, with Stage 1 being mild and Stage 4 being very severe. Measuring peak expiratory flow is of limited value in COPD as it may underestimate the degree of airflow obstruction. It is important to note that the grading system has changed following the 2010 NICE guidelines, with Stage 1 now including patients with an FEV1 greater than 80% predicted but a post-bronchodilator FEV1/FVC ratio less than 70%.

A patient with COPD who is persistently breathless despite regular SABA use needs inhaled treatment added to improve symptom control and prevent exacerbations. The options for add-on inhaled treatment are a LABA+ICS combination inhaler or a LAMA. Adding a regular ICS on its own has no role in the COPD treatment ladder. A regular SAMA can be used instead of a SABA but is not an option for add-in treatment. Adding a LABA can be used in some patients with COPD but is not the priority here. A LABA is usually indicated in patients with an FEV1 of ≥ to 50%. NICE CKS COPD guidelines recommend inhaled bronchodilators as the first-line drugs for the treatment of COPD.

For reference:
SABA – short acting beta agonist
LABA – long acting beta agonist
SAMA – short acting muscarinic antagonist
LAMA – long acting muscarinic antagonist
ICS – inhaled corticosteroid.

Understanding Pulmonary Function Tests

Pulmonary function tests are a useful tool in determining whether a respiratory disease is obstructive or restrictive. These tests measure various aspects of lung function, such as forced expiratory volume in one second (FEV1) and forced vital capacity (FVC). By analyzing the results of these tests, doctors can diagnose and monitor conditions such as asthma, COPD, pulmonary fibrosis, and neuromuscular disorders.

In obstructive lung diseases, such as asthma and COPD, the FEV1 is significantly reduced, while the FVC may be reduced or normal. The FEV1% (FEV1/FVC) is also reduced. On the other hand, in restrictive lung diseases, such as pulmonary fibrosis and asbestosis, the FEV1 is reduced, but the FVC is significantly reduced. The FEV1% (FEV1/FVC) may be normal or increased.

It is important to note that there are many conditions that can affect lung function, and pulmonary function tests are just one tool in diagnosing and managing respiratory diseases. However, understanding the results of these tests can provide valuable information for both patients and healthcare providers.

BTS Guidance on Low Dose ICS and LABA Treatment

According to the 2016 BTS guidance, if a patient taking a low dose ICS doesn’t respond to the addition of a LABA, the LABA should be discontinued. Instead, healthcare providers should consider increasing the dose of ICS. It is important to note that options suggesting only an increase in ICS dose without stopping the LABA are incorrect.

This guidance emphasizes the importance of individualized treatment plans for patients with respiratory conditions. By carefully monitoring patient response to medication and adjusting treatment as needed, healthcare providers can help improve patient outcomes and quality of life. Proper medication management can also help reduce the risk of adverse effects and complications associated with respiratory conditions.

Antibiotic Prophylaxis for Pertussis

When managing a suspected or confirmed case of pertussis, it is important to offer prophylactic antibiotics to reduce transmission if the case presents within 21 days of onset and a vulnerable contact is present in the household. All household contacts, regardless of age or immunisation status, should be offered antibiotics. Antibiotics may not alter the clinical course of the illness, but they can eliminate the organism from the respiratory tract, reducing person-to-person transmission. Vulnerable contacts include newborn infants, unimmunised or partially immunised infants or children up to 10 years, pregnant women, healthcare workers, immunocompromised individuals, and those with chronic illnesses. The maternal pertussis vaccine programme has been highly effective in preventing disease for infants less than 2 months of age. Therefore, the definition of vulnerable infants has been amended to include unimmunised infants born ≤32 weeks, unimmunised infants born >32 weeks whose mothers did not receive maternal pertussis vaccine after 16 weeks and at least 2 weeks before delivery, and infants aged 2 months or over who are unimmunised or partially immunised. It is important for GPs to understand and implement national guidelines for respiratory problems, including the management of pertussis.

An ECG and baseline liver function tests should be performed prior to initiating azithromycin to ensure there is no prolonged QT interval and to establish a baseline for liver function. As the liver function tests in the question stem were normal, the most suitable option would be to conduct an ECG.

The National Institute for Health and Care Excellence (NICE) updated its guidelines on the management of chronic obstructive pulmonary disease (COPD) in 2018. The guidelines recommend general management strategies such as smoking cessation advice, annual influenza vaccination, and one-off pneumococcal vaccination. Pulmonary rehabilitation is also recommended for patients who view themselves as functionally disabled by COPD.

Bronchodilator therapy is the first-line treatment for patients who remain breathless or have exacerbations despite using short-acting bronchodilators. The next step is determined by whether the patient has asthmatic features or features suggesting steroid responsiveness. NICE suggests several criteria to determine this, including a previous diagnosis of asthma or atopy, a higher blood eosinophil count, substantial variation in FEV1 over time, and substantial diurnal variation in peak expiratory flow.

If the patient doesn’t have asthmatic features or features suggesting steroid responsiveness, a long-acting beta2-agonist (LABA) and long-acting muscarinic antagonist (LAMA) should be added. If the patient is already taking a short-acting muscarinic antagonist (SAMA), it should be discontinued and switched to a short-acting beta2-agonist (SABA). If the patient has asthmatic features or features suggesting steroid responsiveness, a LABA and inhaled corticosteroid (ICS) should be added. If the patient remains breathless or has exacerbations, triple therapy (LAMA + LABA + ICS) should be offered.

NICE only recommends theophylline after trials of short and long-acting bronchodilators or to people who cannot use inhaled therapy. Azithromycin prophylaxis is recommended in select patients who have optimised standard treatments and continue to have exacerbations. Mucolytics should be considered in patients with a chronic productive cough and continued if symptoms improve.

Cor pulmonale features include peripheral oedema, raised jugular venous pressure, systolic parasternal heave, and loud P2. Loop diuretics should be used for oedema, and long-term oxygen therapy should be considered. Smoking cessation, long-term oxygen therapy in eligible patients, and lung volume reduction surgery in selected patients may improve survival in patients with stable COPD. NICE doesn’t recommend the use of ACE-inhibitors, calcium channel blockers, or alpha blockers

Treatment options for suboptimal control in COPD patients

To determine the appropriate treatment for suboptimal control in COPD patients, it is recommended to consult the NICE guidance on Chronic obstructive pulmonary disease (CG115). If a patient has suboptimal control despite using a regular short-acting beta 2-agonist (SABA), oral theophylline may be considered at a later stage in the treatment ladder. However, LAMA+LABA should be offered to patients who have spirometrically confirmed COPD, do not have asthmatic features or steroid responsiveness, and remain breathless or have exacerbations despite using a short-acting bronchodilator. It is important to note that adding a regular inhaled steroid is not recommended in the treatment ladder as it is inferior to LABA/ICS combination or LAMA. By following these guidelines, healthcare professionals can provide optimal treatment for COPD patients with suboptimal control.

It is important to note that a patient’s decision to continue smoking should not be a reason to deny them treatment for their asthma. As a healthcare professional, it is your responsibility to bring this to the attention of the doctor involved and discuss the situation with them. This will also give the doctor an opportunity to explain their perspective on the matter. It is not recommended to bring this up during a practice meeting as it may come across as confrontational.

Simply changing the patient’s inhaler treatment will not address the issue of treatment being withheld. It is not acceptable to refuse to adjust their inhalers until they agree to seek smoking cessation treatment, as this can be seen as blackmail. Additionally, removing the patient from the practice list for not quitting smoking is not an appropriate course of action.

If a patient has a known allergy to a sulfa drug like co-trimoxazole, they should avoid taking sulfasalazine.

Sulfasalazine: A DMARD for Inflammatory Arthritis and Bowel Disease

Sulfasalazine is a type of disease modifying anti-rheumatic drug (DMARD) that is commonly used to manage inflammatory arthritis, particularly rheumatoid arthritis, as well as inflammatory bowel disease. This medication is a prodrug for 5-ASA, which works by reducing neutrophil chemotaxis and suppressing the proliferation of lymphocytes and pro-inflammatory cytokines.

However, caution should be taken when using sulfasalazine in patients with G6PD deficiency or those who are allergic to aspirin or sulphonamides due to the risk of cross-sensitivity. Adverse effects of sulfasalazine may include oligospermia, Stevens-Johnson syndrome, pneumonitis/lung fibrosis, myelosuppression, Heinz body anaemia, megaloblastic anaemia, and the potential to color tears and stain contact lenses.

Despite these potential side effects, sulfasalazine is considered safe to use during pregnancy and breastfeeding, making it a viable option for women who require treatment for inflammatory arthritis or bowel disease.

Therapies for Smoking Cessation

There are various therapies available for smoking cessation, including newer drugs that have been specifically developed for this purpose. One such drug is Varenicline, which is a non-nicotine drug that acts as a partial agonist of the alpha-4 beta-2 nicotinic receptor.

Nicotine is a stimulant that releases dopamine in the brain, leading to addictive effects of smoking. However, nicotine replacement therapy can help replace these effects and reduce addiction to cigarette smoking. Bupropion (Zyban) is another drug that reduces the neuronal uptake of dopamine, serotonin, and norepinephrine.

Clonidine is a second-line agent due to its side effects, but it is an a2-noradrenergic agonist that suppresses sympathetic activity. Nortriptyline, a tricyclic antidepressant with mostly noradrenergic properties, is also an effective agent for smoking cessation.

Overall, there are many options available for those looking to quit smoking, and it is important to work with a healthcare provider to determine the best approach for each individual.

Acute exacerbations of COPD are a common reason for hospitalization in developed countries. The most common causes of these exacerbations are bacterial infections, such as Haemophilus influenza, Streptococcus pneumoniae, and Moraxella catarrhalis, as well as respiratory viruses, with human rhinovirus being the most important pathogen. Symptoms of an exacerbation include an increase in dyspnea, cough, and wheezing, as well as hypoxia and acute confusion in some cases.

NICE guidelines recommend increasing the frequency of bronchodilator use and giving prednisolone for five days. Antibiotics should only be given if sputum is purulent or there are clinical signs of pneumonia. Admission to the hospital is recommended for patients with severe breathlessness, acute confusion or impaired consciousness, cyanosis, oxygen saturation less than 90%, social reasons, or significant comorbidity.

For severe exacerbations requiring secondary care, oxygen therapy should be used with an initial saturation target of 88-92%. Nebulized bronchodilators, such as beta adrenergic agonists and muscarinic antagonists, should also be used. Steroid therapy and IV theophylline may be considered, and non-invasive ventilation may be used for patients with type 2 respiratory failure. BiPAP is typically used with initial settings of EPAP at 4-5 cm H2O and IPAP at 10-15 cm H2O.

Understanding Acute Opioid Toxicity

Acute opioid toxicity is a serious condition that can result in drowsiness, nausea, vomiting, and respiratory depression. The severity of symptoms may be exacerbated if alcohol or other sedatives are also involved. Hypotension is a common occurrence, and both tachycardia and bradycardia may be observed. Hypoventilation can lead to hypoxia-induced cardiac arrhythmias, and pinpoint pupils may be present. Sweating is more commonly associated with acute opioid withdrawal. It is important to seek medical attention immediately if you suspect acute opioid toxicity.

The prescription for oxygen is now done through the Home Oxygen Order Form instead of the FP10. Private companies are now responsible for providing the oxygen supply instead of the local pharmacy.

Long-Term Oxygen Therapy for COPD Patients

Long-term oxygen therapy (LTOT) is recommended for patients with chronic obstructive pulmonary disease (COPD) who have severe or very severe airflow obstruction, cyanosis, polycythaemia, peripheral oedema, raised jugular venous pressure, or oxygen saturations less than or equal to 92% on room air. LTOT involves breathing supplementary oxygen for at least 15 hours a day using oxygen concentrators.

To assess patients for LTOT, arterial blood gases are measured on two occasions at least three weeks apart in patients with stable COPD on optimal management. Patients with a pO2 of less than 7.3 kPa or those with a pO2 of 7.3-8 kPa and secondary polycythaemia, peripheral oedema, or pulmonary hypertension should be offered LTOT. However, LTOT should not be offered to people who continue to smoke despite being offered smoking cessation advice and treatment, and referral to specialist stop smoking services.

Before offering LTOT, a structured risk assessment should be carried out to evaluate the risks of falls from tripping over the equipment, the risks of burns and fires, and the increased risk of these for people who live in homes where someone smokes (including e-cigarettes).

Overall, LTOT is an important treatment option for COPD patients with severe or very severe airflow obstruction or other related symptoms.

Process of Elimination in Tricky Questions

When faced with a tricky question, it is important to stay calm and think through the options. One useful technique is the process of elimination. For example, in a question about the best antibiotic for a patient with a penicillin allergy who is taking aminophylline, you can immediately eliminate options that contain penicillin. Macrolides and ciprofloxacin can interact with aminophylline, increasing its plasma concentration, so you can eliminate those options as well. By process of elimination, you can arrive at the best answer, which in this case is doxycycline. Practicing this approach can help you tackle tricky questions and improve your performance in exams. Remember to take your time, read the question carefully, and eliminate options that do not fit the criteria.